Applications

1612 – Prostatic urethral lift procedure for men with benign prostatic hyperplasia

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

The prostatic urethral lift procedure is conducted by installing small permanent implants transurethrally under endoscopic guidance to lift apart the obstructing lateral lobes and reduce urethral obstruction. The procedural objective is to create a channel through the anterior aspect of the prostatic fossa. The implant is comprised of a monofilament with a nitinol capsular tab on one end and a stainless steel urethral end-piece on the other.

Type: Therapeutic

Medical condition this application addresses

BPH is one of the most common diseases of the prostate, characterised by an enlargement of the prostate causing the urethra to narrow and place pressure on the base of the bladder. Narrowing of the urethra can cause problems with the passing of urine in several ways. Benign prostatic hyperplasia (BPH) is often associated with lower urinary tract symptoms (LUTS) which in BPH may be obstructive (includes symptoms such as delay or straining when starting to pass urine, and slow flow of urine) or irritative (includes symptoms such as urgent or frequent urination during the day and night). Furthermore, LUTS associated with BPH are often accompanied by sexual dysfunction, including erectile dysfunction (ED) and ejaculatory problems. While not life-threatening, BPH can be detrimental to a patient’s quality of life. When symptoms of BPH increase in severity, surgical treatment will be considered. Surgical therapy of the prostate is indicated for patients with severe or high impact symptoms.

Meetings to consider this application

  • PASC meeting: Expedited – bypassed PASC
  • ESC meeting: 12 June 2020
  • MSAC meeting: 
    • 28 to 29 July 2020
    • 28 to 29 July 2022